Santen CEO joins OccuLogix board

Before she became president in 2002, Dr. Graves was vice president of clinical affairs for Santen and helped to move three ophthalmic products through the FDA approval process. Prior to her work with Santen, Dr. Graves worked for Alcon Laboratories Inc.

Elias Vamvakas, OccuLogix's chairman and chief executive officer, said the company would benefit from Dr. Graves' involvement in the clinical, regulatory, and commercial development of the RHEO procedure.